We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Celadon Pharmaceuticals Plc | LSE:CEL | London | Ordinary Share | GB00BDQYGP38 | ORD 1P |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 1.50 | 2.52% | 61.00 | 57.00 | 65.00 | 61.00 | 59.50 | 59.50 | 12,246 | 14:00:11 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Investment Advice | 149k | -7.14M | -0.1082 | -5.64 | 39.26M |
Hot Features
Premium
RNS No 3513u
CELSIS INTERNATIONAL PLC
3rd June 1998
CELSIS INTERNATIONAL PLC ("The Company")
As previously announced, Mr Arthur Holden resigned as a
director and chief executive of the Company on 12th May 1998,
having informed the Board of his interest in exploring options
such as acquiring or taking the Company private. Mr Holden
has now notified the Board that he does not intend to make an
offer for the whole Company. Instead, he has offered to
acquire for cash the Celsis Laboratory Group (CLG), the
Company's laboratory services business. The Board, in
consultation with its advisors, has considered Mr Holden's
offer for CLG and has rejected it. Accordingly, there are no
continuing discussions with Mr Holden.
A number of other parties have expressed interest in entering
into discussions with the Company, which may or may not lead
to an offer for the Company. Although the Board is not
seeking a purchaser for the Company, it is reviewing each of
these expressions of interest with its advisors to assess
whether pursuing any of them would be in the best interests of
the Company and its shareholders. A further announcement will
be made in due course.
All enquiries should be directed to:
Chris Evans (Chairman) +44 (0)1873 812028
Mark Harris (Finance Director) +44 (0)1223 426008
END
MSCBIGBLLXGCCID
1 Year Celadon Pharmaceuticals Chart |
1 Month Celadon Pharmaceuticals Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
